179 – Frailty Is Associated With Higher MACE Incidence but Does Not Appear to Modify Pitavastatin Effects
Background People with HIV (PWH) are at increased risk for atherosclerotic cardiovascular diseases (ASCVD) and accelerated aging, including frailty. REPRIEVE demonstrated a 36% reduction in the hazard of major adverse cardiovascular events (MACE) for pitavastatin vs placebo among PWH, but little is known about statins for ASCVD prevention among PWH with frailty. The goal of…